Effects of brodalumab injection: A Synthesis of Findings from 15 Studies

  1. Home
  2. Effects of brodalumab injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of brodalumab injection: A Synthesis of Findings from 15 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of brodalumab injection: A Synthesis of Findings from 15 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Brodalumab is a fully human monoclonal antibody that targets the interleukin-17 receptor A (IL-17RA), a key player in the inflammatory cascade involved in psoriasis. , 11 , 9 . It effectively blocks the biological activities of IL-17A, IL-17F, IL-17A/F, and IL-17E (also known as IL-25). 6 . Studies have shown that brodalumab is effective in treating moderate-to-severe plaque psoriasis, with a significant improvement in skin lesions and an enhanced quality of life for patients. 11 , 6 , 4 , 2 , 1 , 15 , 14 , 8 , 7 , , 5 , , . In certain cases, brodalumab has also been shown to be effective in treating psoriatic arthritis, a condition that affects the joints. 8 . It's also noteworthy that brodalumab appears to be among the most potent IL-17A inhibitors available for psoriasis treatment. 1 . However, brodalumab's mechanism of action, by blocking the IL-17 receptor, can increase the risk of infections. 3 . Side effects such as injection site reactions, oral candidiasis, and flu-like symptoms have also been reported. 2 . Therefore, consulting with a physician before starting brodalumab treatment is crucial. 14 .

Benefits and Risks

Benefit Summary

Brodalumab is a promising treatment for moderate-to-severe plaque psoriasis, offering significant improvement in skin lesions and a better quality of life for patients. 14 . In addition, research suggests that it can effectively manage psoriatic arthritis symptoms. 8 . Brodalumab's potency as an IL-17A inhibitor for psoriasis treatment is considered significant. 1 .

Risk Summary

As a result of its mechanism of action, brodalumab can increase the risk of infections. 3 . Common side effects include injection site reactions, oral candidiasis, and flu-like symptoms. 2 . It's crucial to consult with a physician before starting brodalumab treatment. 14 .

Comparison Between Studies

Commonalities Between Studies

Several studies have consistently demonstrated the effectiveness and safety of brodalumab for the treatment of moderate-to-severe plaque psoriasis. 11 , 6 . Brodalumab has proven to significantly improve skin lesions and enhance the quality of life for patients with psoriasis. 11 , 6 .

Differences Between Studies

The time it takes for brodalumab to achieve its full effect can vary. 1 . There is also some variation in how well brodalumab works for different patients. 1 .

Consistency and Contradictions in Findings

The overall findings regarding brodalumab's effectiveness and safety are consistent across studies. 11 , 6 . However, it is important to note that brodalumab's efficacy can vary significantly between individuals. 1 .

Practical Implications and Considerations

Brodalumab offers a promising treatment option for individuals with moderate-to-severe plaque psoriasis. 11 , 6 . However, it's important to understand the potential risks, including an increased risk of infections and potential side effects. 3 , 2 . Consulting with a physician before starting brodalumab is crucial to determine if it is the right treatment option. 14 .

Limitations of Current Research

Current research has limitations, including the lack of comprehensive long-term data on brodalumab's efficacy and safety. Furthermore, a full understanding of brodalumab's mechanism of action is still under development.

Future Research Directions

Future research should focus on long-term studies to assess brodalumab's long-term effectiveness and safety profiles. Additionally, research is needed to further elucidate the specific mechanisms by which brodalumab functions.

Conclusion

Brodalumab is a promising treatment option for moderate-to-severe plaque psoriasis, offering significant improvement in skin lesions and a better quality of life for patients. 11 , 6 . However, it's important to understand the potential risks, including an increased risk of infections and potential side effects. 3 , 2 . Consulting with a physician before starting brodalumab is crucial to determine if it is the right treatment option. 14 .

Literature analysis of 15 papers
Positive Content
13
Neutral Content
1
Negative Content
1
Article Type
6
1
1
1
15
2.

Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis.

Author: PhanCéline, BenetonNathalie, DelaunayJuliette, ReguiaiZiad, BoulardClaire, FougerousseAnne-Claire, CinottiElisa, RomanelliMarco, Mery-BossardLaure, Thomas-BeaulieuDomitille, ParierJosiane, MaccariFrançois, PerrotJean-Luc, Ruer-MulardMireille, BastienMarie, BegonEdouard, SamimiMahtab, JacobzoneCaroline, Quiles-TsimaratosNathalie, DescampsVincent, SteffMaud, BilanPaul, Vermersch-LanglinAnnie, KemulaMathilde, AmazanEmmanuelle, Kupfer-BessaguetIngrid, CottencinAnne-Caroline, PrignanoFrancesca, LivideanuBulai, GottliebJeremy, BeauchetAlain, MahéEmmanuel,

Good tolerance
Psoriasis treatment
Adverse events
Primary failures
Relapses

Anti-interleukin-17 therapy appears to be an effective and safe therapeutic option for psoriasis treatment in elderly patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

4.

Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.

Author: YamasakiK, NakagawaH, KuboY, OotakiK,

Psoriasis symptom improvement
Nasopharyngitis

Brodalumab, a monoclonal antibody targeting IL-17RA, was found to be effective and safe in treating Japanese patients with generalized pustular psoriasis (GPP) and psoriatic erythroderma (PsE) in this open-label phase III study. After 52 weeks, 11 out of 12 patients with GPP and 18 out of 18 patients with PsE achieved remission or improvement, with the most common side effect being nasopharyngitis (33.3%).

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

5.

Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data.

Author: FarahnikBenjamin, BeroukhimKourosh, NakamuraMio, AbroukMichael, ZhuTian Hao, SinghRasnik, LeeKristina, BhutaniTina, KooJohn

Promising treatment

This review summarizes the evidence highlighting the vital role of IL-17 in the pathogenesis of psoriasis. Preclinical and Phase II studies focusing on IL-17 and its receptor show promise for treating this disease.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.

Author: NakagawaHidemi, NiiroHiroaki, OotakiKenji,

Psoriasis treatment

This study investigated the efficacy of brodalumab in treating patients with moderate to severe plaque psoriasis in a 12-week phase 2 trial in the USA, Europe, and other countries.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate.

Author: PavelkaKarel, ChonYun, NewmarkRichard, LinShao-Lee, BaumgartnerScott, EronduNgozi

Cardiopulmonary failure

A randomized controlled trial found no evidence of meaningful clinical efficacy with brodalumab treatment in subjects with rheumatoid arthritis who had an inadequate response to methotrexate.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.

Author: MeasePhilip J, GenoveseMark C, GreenwaldMaria W, RitchlinChristopher T, BeaulieuAndré D, DeodharAtul, NewmarkRichard, FengJingYuan, EronduNgozi, NirulaAjay

Improved psoriatic arthritis symptoms
Serious adverse events

Brodalumab significantly improved response rates among patients with psoriatic arthritis. Larger studies of longer duration are necessary to assess adverse events.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis.

Author: MartinDavid A, ChurchillMelvin, Flores-SuarezLuis, CardielMario H, WallaceDaniel, MartinRichard, PhillipsKristine, KaineJeffrey L, DongHua, SalingerDavid, StevensErin, RussellChris B, ChungJames B

RA treatment
Opportunistic infections

This study evaluated the safety, pharmacokinetics, and clinical response of brodalumab, a human, anti-IL-17 receptor A (IL-17RA) monoclonal antibody, in subjects with moderate-to-severe rheumatoid arthritis (RA). The study found that brodalumab was generally tolerated but there was no evidence of a clinical response.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma.

Author: BusseWilliam W, HolgateStephen, KerwinEdward, ChonYun, FengJingyuan, LinJoseph, LinShao-Lee

Improved ACQ score
Improved FEV1
Reduced symptoms
Asthma
Injection site reaction
Upper respiratory infection

Brodalumab, an anti-IL-17 receptor A monoclonal antibody, did not show efficacy in treating asthma. However, in a subgroup analysis, a nominal significance was observed for ACQ change in the high-reversibility subgroup (post-bronchodilator FEV1 improvement ≥ 20%). Further study of brodalumab in this subpopulation is needed.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

Author: PappKim A, LeonardiCraig, MenterAlan, OrtonneJean-Paul, KruegerJames G, KricorianGregory, ArasGirish, LiJuan, RussellChris B, ThompsonElizabeth H Z, BaumgartnerScott

Improved psoriasis
Neutropenia

This phase 2, randomized, double-blind, placebo-controlled study assessed the efficacy and safety of brodalumab in 198 patients with moderate to severe plaque psoriasis. Brodalumab significantly improved psoriasis area-and-severity index (PASI) scores compared to placebo at week 12. The most common adverse events were nasopharyngitis, upper respiratory tract infection, and injection-site erythema.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

English version of Japanese guidance for use of biologics for psoriasis (the 2022 version).

Author: SaekiHidehisa, MabuchiTomotaka, AsahinaAkihiko, AbeMasatoshi, IgarashiAtsuyuki, ImafukuShinichi, OkuboYukari, KomineMayumi, SanoShigetoshi, ToriiHideshi, MoritaAkimichi, YotsuyanagiHiroshi, WatanabeAkira, OhtsukiMamitaro,

Improved psoriasis
Administration-related reactions
Infections

This guidance provides recommendations for the appropriate use of biologics in the treatment of psoriasis in Japan. It emphasizes the importance of selecting the most suitable biologic therapy for each patient based on disease factors, treatment factors, and patient background factors. The guidance outlines key considerations for selecting biologics, including drug effects, safety, convenience, and cost.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

Japanese guidance for use of biologics for psoriasis (the 2019 version).

Author: SaekiHidehisa, TeruiTadashi, MoritaAkimichi, SanoShigetoshi, ImafukuShinichi, AsahinaAkihiko, KomineMayumi, EtohTakafumi, IgarashiAtsuyuki, ToriiHideshi, AbeMasatoshi, NakagawaHidemi, WatanabeAkira, YotsuyanagiHiroshi, OhtsukiMamitaro,

Psoriasis Treatment

This guidance for dermatologists focuses on the selection of appropriate biologic therapies for psoriatic patients in Japan. It considers key factors including drug effects, safety, convenience, and cost, to assist physicians in making informed decisions about biologic therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Practice GuidelineGuidelines and recommendations for the diagnosis and treatment of specific medical conditions in medical practice.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.